Patterns of progression and subsequent management of patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib versus placebo: the SOLO2/ENGOT Ov-21 trial (NCT01874353).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6070
Abstract: 6070Background: Olaparib maintenance is a standard treatment of BRCA1/2 mutated platinum-sensitive recurrent EOC. Despite improvement in PFS, olaparib (O) resistance often occurs and the optimal ma... read more here.
Keywords: platinum sensitive; mutated platinum; sensitive recurrent; brca1 mutated ... See more keywords
Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02085
Abstract: PURPOSE The survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied. METHODS We identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and Cochrane… read more here.
Keywords: sensitive recurrent; recurrent ovarian; platinum sensitive; analysis ... See more keywords
A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15102869
Abstract: Simple Summary This study aimed to determine the optimal maintenance therapy and selection criteria for patients with platinum-sensitive recurrent ovarian cancer (PSROC). The study collected retrospective data from 51 patients with PSROC and found that… read more here.
Keywords: sensitive recurrent; platinum sensitive; therapy; maintenance therapy ... See more keywords